Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni (original) (raw)

Schistosomiasis is a significant health issue, affecting over 200 million worldwide. With concerns surrounding the efficacy of praziquantel (PZQ) due to potential resistance, mefloquine (Mef) emerges as a promising alternative with schistosomicidal properties. In this study, combination therapy using PZQ and Mef was examined in mice with Schistosoma mansoni. Results demonstrated that combining Mef and PZQ significantly enhanced therapeutic efficacy, showing greater reductions in both mature and immature worm populations compared to PZQ alone. This supports further clinical investigation of PZQ and Mef combination therapy as a viable treatment option.